Compare RVMD & DRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVMD | DRI |
|---|---|---|
| Founded | 2014 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 25.9B |
| IPO Year | 2020 | 2000 |
| Metric | RVMD | DRI |
|---|---|---|
| Price | $190.67 | $209.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 25 |
| Target Price | $140.84 | ★ $226.50 |
| AVG Volume (30 Days) | ★ 1.6M | 715.7K |
| Earning Date | 05-06-2026 | 03-19-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | N/A | ★ 17.16 |
| EPS | N/A | ★ 10.38 |
| Revenue | N/A | ★ $13,210,900,000.00 |
| Revenue This Year | N/A | $10.58 |
| Revenue Next Year | $533.02 | $3.73 |
| P/E Ratio | ★ N/A | $19.92 |
| Revenue Growth | N/A | ★ 9.39 |
| 52 Week Low | $42.18 | $169.00 |
| 52 Week High | $224.31 | $229.76 |
| Indicator | RVMD | DRI |
|---|---|---|
| Relative Strength Index (RSI) | 34.73 | 45.49 |
| Support Level | $177.04 | $189.02 |
| Resistance Level | $194.19 | $212.53 |
| Average True Range (ATR) | 7.15 | 4.78 |
| MACD | -2.74 | -1.21 |
| Stochastic Oscillator | 6.27 | 17.89 |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Darden Restaurants is the largest global full-service dining operator, with over $12 billion in system sales across 2,159 company-owned stores at the end of fiscal 2025, spanning the US and Canada. The firm operates 10 banners in four segments, including Olive Garden (43% of sales), LongHorn Steakhouse (25%), and fine dining (21%), which includes The Capital Grille, Ruth's Chris, and Eddie V's. The other 11% of sales comes from smaller concepts such as Yard House and Cheddar's. Darden primarily generates revenue through sales of food and beverage items at its company-owned restaurants. It also earns royalties on sales from 154 franchised locations in US and international markets, which sit within the other segment but are immaterial to consolidated results.